Skip to content

AVALO THERAPEUTICS, INC.: 10-Q filed 2017-08-14

What AVALO THERAPEUTICS, INC. reported in its quarterly report filed 2017-08-14 (fiscal Q2 2017): 22 published measures, 56 facts as tagged in accession 0001628280-17-008646.

This filing

Form
10-Q (quarterly report)
Filed
2017-08-14
Fiscal period
fiscal Q2 2017
Accession
0001628280-17-008646 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All AVALO THERAPEUTICS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2017-06-306,047,731USD
At 2016-12-315,768,865USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2017-06-302,912,236USD
At 2016-12-315,561,863USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2017-06-303,135,495USD
At 2016-12-31207,002USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2017-06-305,460,699USD
At 2016-12-315,127,958USD
At 2016-06-3011,879,545USD
At 2015-12-3121,161,967USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2017-04-01 to 2017-06-30-1,798,515USD91
2017-01-01 to 2017-06-30-3,759,152USD181
2016-04-01 to 2016-06-30-3,524,160USD91
2016-01-01 to 2016-06-30-8,664,174USD182

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2017-01-01 to 2017-06-301,801USD181
2016-01-01 to 2016-06-3019,157USD182

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2017-06-30-73,794,235USD
At 2016-12-31-70,035,083USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2017-06-3033,355USD
At 2016-12-3143,243USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2017-01-01 to 2017-06-30587,963USD181
2016-01-01 to 2016-06-301,151,420USD182

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2017-04-01 to 2017-06-30-1,774,995USD91
2017-01-01 to 2017-06-30-3,674,123USD181
2016-04-01 to 2016-06-30-3,488,037USD91
2016-01-01 to 2016-06-30-8,430,405USD182

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2017-06-305,951,535USD
At 2016-12-315,662,794USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2017-06-301,662,236USD
At 2016-12-314,311,863USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2017-06-30327,302USD
At 2016-12-311,010,209USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2017-04-01 to 2017-06-30493,649USD91
2017-01-01 to 2017-06-301,446,719USD181
2016-04-01 to 2016-06-302,501,753USD91
2016-01-01 to 2016-06-304,795,028USD182

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2017-06-3014,114,859shares
At 2016-12-319,434,141shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2017-06-3076,915,611USD
At 2016-12-3170,232,651USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2017-06-30402,294USD
At 2016-12-31391,253USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2017-04-01 to 2017-06-301,439,146USD91
2017-01-01 to 2017-06-302,769,410USD181
2016-04-01 to 2016-06-301,636,772USD91
2016-01-01 to 2016-06-304,285,865USD182

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2017-01-01 to 2017-06-3011,689USD181
2016-01-01 to 2016-06-3013,416USD182

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2017-04-01 to 2017-06-30-23,520USD91
2017-01-01 to 2017-06-30-85,029USD181
2016-04-01 to 2016-06-30-36,123USD91
2016-01-01 to 2016-06-30-233,769USD182

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2017-01-01 to 2017-06-301,693,498USD181
2016-01-01 to 2016-06-300USD182

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2017-01-01 to 2017-06-30-682,907USD181
2016-01-01 to 2016-06-3061,193USD182

Inspect the source

Entity
AVALO THERAPEUTICS, INC. / CIK 0001534120
Captured
2026-09-20T09:16:35.394Z
SEC response SHA-256
c27cef5388033067af62e0489a1b2af90f086713b680df0f63e0f63ad2ea1ca3

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001534120.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))